Diversified Investment Strategies Lowers stake in Dolby Laboratories (DLB)

Dolby Laboratories (DLB) : Diversified Investment Strategies reduced its stake in Dolby Laboratories by 3.79% during the most recent quarter end. The investment management company now holds a total of 61,500 shares of Dolby Laboratories which is valued at $2.8 Million after selling 2,425 shares in Dolby Laboratories , the firm said in a disclosure report filed with the SEC on May 12, 2016.Dolby Laboratories makes up approximately 2.97% of Diversified Investment Strategies’s portfolio.

Other Hedge Funds, Including , Denver Investment Advisors added DLB to its portfolio by purchasing 271,914 company shares during the most recent quarter which is valued at $12.4 Million. Dolby Laboratories makes up approx 0.56% of Denver Investment Advisors’s portfolio. Blackrock Japan Ltd sold out all of its stake in DLB during the most recent quarter. The investment firm sold 3,918 shares of DLB which is valued $178,465.Baillie Gifford Co boosted its stake in DLB in the latest quarter, The investment management firm added 66,369 additional shares and now holds a total of 5,634,878 shares of Dolby Laboratories which is valued at $255.7 Million. Dolby Laboratories makes up approx 0.46% of Baillie Gifford Co’s portfolio.Apex Capital Management boosted its stake in DLB in the latest quarter, The investment management firm added 19,213 additional shares and now holds a total of 876,285 shares of Dolby Laboratories which is valued at $41.7 Million. Dolby Laboratories makes up approx 0.92% of Apex Capital Management’s portfolio.

Dolby Laboratories opened for trading at $44.33 and hit $45.065 on the upside on Friday, eventually ending the session at $44.97, with a gain of 1.65% or 0.73 points. The heightened volatility saw the trading volume jump to 2,69,938 shares. Company has a market cap of $4,509 M.

On the company’s financial health, Dolby Laboratories reported $0.82 EPS for the quarter, beating the analyst consensus estimate by $ 0.21 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.61. The company had revenue of $274.30 million for the quarter, compared to analysts expectations of $263.96 million. The company’s revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.72 EPS.

Many Wall Street Analysts have commented on Dolby Laboratories. Company shares were Reiterated by Dougherty & Company on Apr 28, 2016 to “Buy”, Firm has raised the Price Target to $ 54 from a previous price target of $46 .Company shares were Reiterated by Dougherty & Company on Apr 25, 2016 to “Buy”, Firm has raised the Price Target to $ 46 from a previous price target of $38 .Dolby Laboratories was Downgraded by JP Morgan to ” Neutral” on Apr 8, 2016.

Dolby Laboratories Inc. (Dolby Laboratories) creates audio imaging and communication technologies that transform entertainment and communications at the cinema at home at work and on mobile devices. The Company licenses its audio technologies and also develops technologies aimed at enhancing voice conferencing communications and imaging. Additionally the Company provides products and services that enable entertainment content creators and distributors to produce encode transmit and playback content for consumer experiences. The Company designs and manufactures audio and imaging products for the film production cinema and television broadcast industries. Distributed in approximately 80 countries these products are used in content creation distribution and playback to enhance image and sound quality and improve transmission and playback.

Leave a Reply

Dolby Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Dolby Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.